4751-48-8

Basic information

• Product Name: ST 91
• Synonyms: ST 91;2-(2,6-Diethylphenylamino)-2-imidazolidine;4749-61-5 (Mono-hydrochloride);N-(2,6-Diethylphenyl)-4,5-dihydro-1H-imidazol-2-amine
• CAS NO: 4751-48-8
• Molecular Formula: C₁₃H₁₉N₃
• Molecular Weight: 217.31006
• Mol File: 4751-48-8.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 325.1°Cat760mmHg
• Flash Point: 150.4°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 0.000235mmHg at 25°C
• CAS DataBase Reference: ST 91(CAS DataBase Reference)
• NIST Chemistry Reference: ST 91(4751-48-8)
• EPA Substance Registry System: ST 91(4751-48-8)

Safety Data

• Hazardous Substances Data: 4751-48-8(Hazardous Substances Data)

Usage

Uses

ST 91 is an a2B-adrenoceptor agonist.

InChI:InChI=1/C13H19N3.ClH/c1-3-10-6-5-7-11(4-2)12(10)16-13-14-8-9-15-13;/h5-7H,3-4,8-9H2,1-2H3,(H2,14,15,16);1H

Upstream product

• 61939-90-0 2-[N-propargyl-N-(2',6'-diethyl-phenyl)-amino]-2-imidazoline 
• 579-66-8 2,6-diethylaniline 
• 5391-39-9 1-acetylimidazolidin-2-one 
• 86861-31-6 1-acetyl-N-(2,6-diethylphenyl)-4,5-dihydro-1H-imidazol-2(3H)-imine 

Downstream Products

• 86861-32-7 N-(2,6-diethyl-4-nitrophenyl)-4,5-dihydro-1H-imidazol-2(3H)-imine 
• 86861-33-8 2,6-Diethyl-3-nitro-N-(2-imidazolidinylidene)-benezenamine 
• 86861-20-3 2,6-Diethyl-N₁-(2-imidazolidinylidene)-1,4-benzenediamine 
• 121158-56-3 N-(4-azido-2,6-diethyl<3,5-(3)H2>phenyl)-4,5-dihydro-1H-imidazol-2(3H)-imine 
• 121158-53-0 N-(4-azido-2,6-diethylphenyl)-4,5-dihydro-1H-imidazol-2(3H)-imine 
• 121158-55-2 C₁₃H₁₈⁽³⁾H₂N₄ 
• 121158-54-1 2,6-dibromo-4-[(4,5-dihydro-1H-imidazol-2(3H)-ylidene)amino]-3,5-diethylbenzenamine 

Relevant articles and documents

Method for treating central nervous system disorders with substituted 2-imidazoline derivatives

The present invention relates to a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, X, A, and n are as defined in the specification and pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms thereof.

Three-dimensional common-feature hypotheses for octopamine agonist 2-(arylimino)imidazolidines

Three-dimensional pharmacophore hypotheses were built from a set of 10 octopamine (OA) agonist 2-(Arylimino)imidazolidines (AIIs), 2-(Arylimino)thiazolidines (AITs) and 2-(Arylimino)oxazolidines (AIOs). Among the 10 common-featured models generated by program Catalyst/HipHop, a hypothesis including a ring aromatic (RA), a positive ionizable (PI) and three hydrophobic aliphatic (HpA1) features was considered to be important in evaluating the OA-agonist activity. Active OA agonist 2,6-Et2 AII mapped well onto all the RA, PI and HpAl features of the hypothesis. On the other hand, less active compounds were shown to be difficult to achieve the energetically favorable conformation which is found in the active molecules in order to fit the 3-D common-feature pharmacophore models. Taken together, 2,6-Et2-Ph and foramidine structures are important as OA agonists. The present studies on OA agonists demonstrate that a RA, a PI and three HpAl sites located on the molecule seem to be essential for OA-agonist activity. Copyright

A probe for octopamine receptors: Synthesis of 2-[(4-azido-2,6-diethylphenyl)imino]imidazolidine and its tritiated derivative, a potent reversible-irreversible activator of octopamine-sensitive adenylate cyclase

In order to develop an irreversible ligand for octopamine receptors, a highly potent azido-substituted 2-(phenylimino)imidazolidine (NC-5Z, 8) and its tritiated derivative (3H-NC-5Z, 11) have been designed and synthesized. Under reversible-binding conditions, NC-5Z is 50-100-fold more potent than octopamine in activating octopamine-sensitive adenylate cyclase in a variety of tissues. After photolysis, 3H-NC-5Z binds irreversibly to cell membranes, and this binding is reduced by preincubation with octopamine agonists and antagonists but not by norepinephrine, dopamine, serotonin, or histamine. NC-5Z should be useful both as a potent reversible octopamine agonist and as an affinity probe for characterizing and isolating octopamine-receptor proteins.